J-2H1702 by J2H Biotech for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
J-2H1702 is under clinical development by J2H Biotech and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the J-2H1702 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.J-2H1702 overviewJ-2H1702 is under development for the treatment of non-alcoholic steatohepatitis (NASH). It is administered through oral route.J2H Biotech overviewJ2H Biotech, is a biopharmaceutical company that develops synthetic drugs and generic drugs for rare intractable diseases, infectious diseases and liver diseases. The company is headquartered Republic of Korea (South Korea). For a complete picture of J-2H1702's drug-specific PTSR and LoA scores, buy the report here.
J-2H1702 is under clinical development by J2H Biotech and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What's Your Reaction?
